Respiratory tract infection
Conditions
Interventions
Intervention group:The Probiotic A product (with specific ingredients including CCFM1279, CCFM1145, CCFM1127, root powder, dihydroquercetin, resistant dextrin, fructooligosaccharides, pineapple powder
Lacebo group:Administer Probiotic B product (with xylitol and resistant dextrin as specific ingredients, produced by Wuxi Pharmaceutical Technology Branch of Shanghai Haiwei Biological Technology Co.,
Sponsors
Wuxi people’s Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Age over 60 years old, with a stable chronic disease condition. 2. It can be used in conjunction with the collection of experimental specimens and regular follow-up visits. 3. The subjects signed the consent form for the study. For those with dementia, their legal guardians were required to sign the consent form on their behalf.
Exclusion criteria
Exclusion criteria: 1. Subjects with severe cardiovascular diseases (myocardial infarction, heart failure), liver/kidney failure, cancer, and those expected to have a short survival period in the near future. 2. Subjects who have consumed probiotic-related products (powder, yogurt, milk, or other fermented foods) continuously (for five days or more) within the last 1 month. 3. Subjects who have participated in other clinical trials and are currently using the trial drugs. 4. Other subjects who, after assessment by the physician, are not suitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal analysis;TNF-a;IL-1ß;IL-6;IFN-ß;The occurrence of influenza events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Blood routine test;renal function;Duration of respiratory tract infection;Duration of respiratory tract infection;Complications of respiratory tract infection.; | — |
Countries
China
Contacts
Public ContactLu Shourong
Wuxi people’s Hospital
Outcome results
None listed